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Abstract 
CELF2 belongs to the family of RNA binding 
proteins implicated in mRNA splicing, editing, 
stability and translation.  
This gene is encoded in a single large gene 
spanning over 159 kilo bases located on 
chromosome 10 p13-p14 (between D10S547 and 
D10S223).  
This gene has 14 transcripts (splice variants) and 
the 3 major splice variants have distinct exon 1. 
This is an evolutionarily conserved ubiquitously 
expressed protein. The members of the CELF 
protein family contain two N-terminal RNA 
recognition motif (RRM) domains and one C-
terminal RRM domain, and a divergent segment of 
160-230 amino acids between second and third 
RRM domains. This divergent domain is unique to 
CELF2 proteins and has been shown to contain one 
or more activation molecules required for splicing 
activity. CELF2 has been shown to bind to the 
CUG and Au-rich element (ARE) in the target 
mRNA and shown to be implicated in muscular 
dystrophy and cancer. 
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Identity 
Other names: BRUNOL3, CUGBP2, ETR-3, 
ETR3, NAPOR 
HGNC (Hugo): CELF2 
Location: 10p14 
Note: Size: 331416 bases. Orientation: plus strand.  
This gene is encoded by a gene located on 
chromosome 10p13-p14 between Généthon 
markers D10S547 and D10S223 (Li et al., 2001). 
DNA/RNA 
Description 
The human CELF2 gene contains 14 exons 
spanning over approximately 159 kb of the 
genomic DNA. 
Transcription 
Alternative promoters usage of CELF2 gene results 
in three transcript variants, where the variants 2 and 
3 proteins have distinct exon 1 resulting in different 
5' untranslated region (UTR) and have extended N-
terminal sequences (Ramalingam et al., 2008). 
There are totally 14 transcripts (splice variants) 
reported so far. 
Protein 
Description 
This is an evolutionarily conserved protein. The 
members of the CELF protein family contain two 
N-terminal RNA recognition motif (RRM) domains 
and one C-terminal RRM domain, and a divergent 
segment of 160-230 amino acids between second 
and third RRM domains. This divergent domain is 
unique to CELF2 proteins and has been shown to 
contain one or more activation molecules required 
for splicing activity (figure 1). 
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Figure 1. RRM position of CELF2 protein variants. 
 
Expression 
CELF2 is a ubiquitously expressed protein. 
According to the NCBI Entrez GEO profiles the 
CELF2 is expressed in brain, heart, thymus, spleen, 
bone, tongue, stomach, intestine, pancreas, liver, 
breast, lung, kidney, testis, ovary, prostate, placenta 
and skin. In addition, according to expression atlas 
brain, bone marrow, heart, spleen, lymph node, 
ovary and adipose tissue has more expression of 
CELF2. 
Localisation 
CELF2 variant 1 is predominantly nuclear, while 
variants 2 and 3 are predominantly cytoplasmic 
(Ramalingam et al., 2008). CELF2 variant 1 
accumulates in the cytoplasm following radiation 
exposure (Mukhopadhyay et al., 2003a). The C 
terminus of CELF2 transcript variant 1 is rich in 
arginine and lysine residues 13 amino acids 
(KRLKVQLKRSKND) 467 - 480, which is 
common for NLS elements recognized by importin 
proteins. Ladd and Cooper, has reported that the C-
terminus of CELF2 contains a strong nuclear 
localization signal overlapping the third RRM 
(Ladd and Cooper, 2004). However, our 
unpublished data suggests that nuclear localization 
signal extends to the RNA recognition motif 1 and 
2 domains. Finally, CELF2 has several leucine-rich 
motifs that resembles nuclear export signals 
recognized by the export protein CRM1. 
Function 
CELF2 is an RNA-binding protein implicated in the 
regulation of several post-transcriptional events. It 
has been shown to regulate pre-mRNA splicing 
(Faustino and Cooper, 2005), mRNA editing 
(Anant et al., 2001), mRNA translation and 
stability. CELF2 has been shown to be involved in 
alternative splicing of muscle specific genes 
including exon 5 of cardiac troponin T (Ladd et al., 
2001), exon 11 of insulin receptor, intron 2 of 
chloride channel 1, exons 5 and 21 of NMDAR-1, 
and the muscle-specific exon of α-actinin (Gromak 
et al., 2003). Another function for CELF2 relates to 
its ability to bind to AU-rich sequences in 3' 
untranslated region (3' UTR) of the target mRNAs. 
Upon binding to the AU-rich sequences in 
cyclooxygenase-2 (COX-2) 3' UTR, CELF2 
enhances the stability of COX-2 mRNA. However, 
CUGBP2 binding also results in the inhibition of its 
translation (Murmu et al., 2004). In our earlier 
studies we have demonstrated that CELF2 can 
interact with HuR, a key inducer of RNA stability 
and translation, and competitively inhibit HuR 
function (Sureban et al., 2007). Recently, platelet 
derived growth factor was shown to enhance 
CELF2 binding to COX-2 mRNA through 
increased phosphorylation of a tyrosine residue at 
position 39 in the protein (Xu et al., 2007). These 
data suggest that posttranscriptional control 
mechanisms are in place to modulate the CELF2 
function as a regulator of stability and translation of 
AU-rich transcripts. 
Homology 
According to GeneCards, the CELF2 has orthologs 
in 72 species including much lower organisms such 
as Danio rerio, Drosophila melanogaster, 
Caenorhabditis elegans, Xenopus tropicalis and 
Oryza sativa. Furthermore, in humans it has 6 
paralogs from CELF1 to CELF6. 
Mutations 
Note 
According to GeneCards, there is 7518 single 
nucleotide polymorphism. However, Ensembl 
reports that CELF2 has 7768 SNPs. In addition, the 
Database of Genomic Variants shows that CELF2 
has 18 structural variations. 
Implicated in 
Colon cancer 
Note 
Putative tumor suppressor CELF2 expression is 
consistently reduced during neoplastic 
transformation suggesting that it might play a 
crucial role in tumor initiation and progression of 
colon cancer. In addition, CELF2 has been shown 
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to induce mitotic catastrophic cell death in colon 
cancer (Ramalingam et al., 2012). 
Pancreatic cancer 
Note 
Curcumin inhibits the pancreatic cancer growth by 
inducing the expression of CELF2 thereby 
regulating the levels of cyclooxygenase 2 and 
vascular endothelial growth factor expression 
(Subramaniam et al., 2011). 
Breast cancer 
Note 
Breast cancer cells underwent apoptotic cell death 
in response to radiation injury and this was reversed 
by knockdown of CELF2 using specific siRNA 
(Mukhopadhyay et al., 2003b). 
Neuroblastoma 
Note 
Colchicine treatment of neuroblastoma cells 
resulted in apoptotic cell death and CELF2 has been 
shown to be involved in the process of cell death 
(Li et al., 2001). 
Alzheimer's disease 
Note 
It has been shown that variants in CUGBP2 on 
chromosome 10p, are associated with AD in those 
highest-risk APOE e4 homozygotes. This 
interaction observation is replicated in independent 
samples. CELF2 has one isoform that is expressed 
predominantly in neurons, and identification of 
such a new risk locus is important because of the 
severity of AD (Wijsman et al., 2011). 
Heart disease 
Note 
Arrhythmogenic right ventricular dysplasia is the 
most common cause of sudden cardiac death in the 
young in Italy and the second most common cause 
in the United States. One of the genes that was 
mapped to this is in the vicinity of chromosome 
10p12-p14 and it is CELF2 (Li et al., 2001). 
Ischemia 
Note 
The transient global ischemia induces the 
translational inhibition of genes with increased 
expression in normothermic mice. The author's 
correlate the translational inhibition with CELF2 
expression and this might play an important role in 
the progress of neuronal injury after transient global 
ischemia (Otsuka et al., 2009). 
Atrophy 
Note 
The differential expression of CELF2 has been 
confirmed with real-time RT-PCR in spinal cord 
and muscle of three different models of spinal 
muscular atrophy (Anderson et al., 2004). Spinal 
and bulbar muscular atrophy (SBMA) is an 
inherited neurodegenerative disorder caused by the 
expansion of the polyglutamine (polyQ) tract of the 
androgen receptor (AR-polyQ). It has been shown 
that miR-196a enhanced the decay of the AR 
mRNA by silencing CUGBP, Elav-like family 
member 2 (CELF2). CELF2 shown to directly act 
on AR mRNA and enhance the stability of AR 
mRNA (Miyazaki et al., 2012). Myotonic 
dystrophy (DM) is a neuromuscular disorder 
associated with CTG triplet repeat expansion in the 
myotonin protein kinase gene (DMPK). It has been 
suggested that the expanded CUG repeats sequester 
specific RNA-binding proteins and that such a 
sequestration results in abnormal RNA processing 
of several RNAs containing CUG repeats in 
multiple tissues affected in patients with DM. One 
of the members of the CUG-binding proteins, 
CUG-BP, has been identified previously (Lu et al., 
1999). 
Development 
Note 
Overexpression of CELF2 by RNA microinjection 
resulted in severe defects in nervous system and 
gastrulation, suggesting the need for tight control of 
napor gene regulation during embryo development 
(Choi et al., 2003). CELF2 appears to be an 
important factor for thymus development and is 
therefore a candidate gene for the thymus 
hypoplasia/aplasia seen in partial monosomy 10p 
patients (Lichtner et al., 2002). 
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